A

abortion, spontaneous: 6, 46
activated partial thromboplastin time: 23
activities of daily living (ADL): 29, 35, 41, 44, 45, 69, 88
adrenaline: 14
African American: 10
alcoholism: 56
allele: 12, 13
allergy: 48, 55, 60, 61, 82
alopecia: 3, 15, 27, 32, 56, 60
American College of Rheumatology: 3, 4, 14, 123
amylase, serum: 43
anemia: 3, 4, 7, 21, 27, 28, 35, 36, 39, 60, 62
anger: 7, 29, 30, 42, 65, 66, 75, 84
animal: 11-14, 16
anorexia: 27, 39, 42, 43, 49, 54
antibiotics: 6, 14, 40, 53, 90, 113
anticardiolipin: 3, 22, 35, 45
anticardiolipin antibodies: 23
anticoagulants: 23, 27
anticonvulsants: 53
antihypertensives: 53
antimalarials: 6, 42-44, 55, 56, 57, 85, 105, 113
antinuclear antibodies: 3, 11, 21
antiphospholipid antibodies: 4, 17, 22, 35
anxiety: 29, 41, 61, 75, 76
apoptosis: 13
appetite: 28, 56, 85, 95, 105, 108, 111
arterial thrombosis: 37
arthralgia: 3, 27, 33, 87
arthritis: 2-4, 14, 16, 17, 21, 27, 33, 55, 59, 69, 84, 87, 105, 108, 109, 115
Arthritis Foundation: 8, 124
ascites: 27, 42, 43
Association of Rheumatology Health Professionals: 123
atherosclerosis: 36, 37, 83, 96
autoantibodies: 3, 11-14, 21, 22, 45
azathioprine: 43, 59, 60, 61, 109

B

B cells: 14
baldness (see also alopecia): 89
biologic agents: 16
biopsy:

kidney: 24, 38
skin: 31
bladder cancer: 15
bladder fibrosis: 15
blindness: 41, 44, 85
body hair, increased (see hirsutism)
bone marrow: 35, 60
bruising: 27, 32, 36, 103, 105, 109
butterfly rash (see also malar rash): 27, 31, 32, 89, 129


C

C-reactive protein: 22
Candida: 48
cardiolipin: 23
cardiovascular (see also under specific
disorders)
disease: 49, 96
side effects of drugs: 54, 58
carpal tunnel syndrome: 34, 87
cataracts: 15, 44, 58, 85
CBC: 3, 55, 56, 59-61
CellCept©: 15, 59, 117
children of patients: 7, 66, 67
chloroquine: 55
chlorpromazine: 14
CNS: 27, 40, 41, 45, 83
coagulation: 23
cognitive impairment: 27, 40, 41
combination therapies: 16
complement: 3, 12, 13, 22, 73, 74
congestive heart failure: 58
conjunctivitis: 44
connective tissue disease: 21
contraception: 6, 60
coping skills: 42, 66, 68
coronary artery disease: 15
corticosteroids: 6, 15, 22, 28, 30-32, 35, 38, 42-44, 46, 48, 56-59, 61, 74, 76, 84, 85, 89, 91, 93, 95, 96, 99, 101, 107-109, 111
counseling: 5, 30, 39, 42, 45
creatinine: 23, 24, 39, 54, 61
criteria, American College of
Rheumatology: 4
Cushing's syndrome: 58
cyclophosphamide: 15-17, 43, 59, 60, 111
cyclosporine: 43, 59, 60, 115
cytoid bodies: 27, 44
cytotoxic: 35, 38, 42

D

dehydroepiandrosterone: 16, 62
depression: 7, 28-30, 32, 41, 42, 49, 58, 65, 68, 75, 76, 83, 84, 108
dermatological (see also rash; skin)
manifestations: 27, 31, 32
nursing interventions: 33
side effects of drugs: 56, 58, 60, 61
dexamethasone: 57
diabetes: 15, 46, 49, 58, 61, 96, 108
diagnosis: 2, 65, 75
dialysis: 38
diclofenac sodium: 54
diet: 4, 5, 28, 30, 33, 37, 39, 43, 48-50, 77, 82, 95, 96, 100, 108
diflunisal: 54
dilute Russell viper venom time: 23
discoid lesions: 89
discoid lupus: 1, 31, 55, 76, 105
discoid rash: 4
diuretics: 53, 90
drug-induced lupus: 2
drugs (see also under specific drugs)
activators of SLE: 2
antibiotics: 6, 14, 40, 53, 90, 113
anticoagulants: 23, 27
anticonvulsants: 53
antihypertensives: 53
antimalarials: 6, 42-44, 55-57, 85, 105, 113
combination therapies: 16
corticosteroids: 6, 15, 22, 28, 30-32, 35, 38, 42-44, 46, 48, 56-59, 61, 74, 76, 84, 85, 89, 91, 93, 95, 96, 99, 101, 107-109, 111
cytotoxics: 35, 38, 42
diuretics: 53, 90
education of patients: 6, 39, 40, 44, 53
immunosuppressives: 6, 15, 29, 48, 59-61, 91, 109
NSAIDs: 6, 35, 42, 54, 55, 57, 93, 103
oral contraceptives: 6, 15, 17, 47
patient history: 2, 5, 6, 20, 55, 57, 58, 60, 61
pregnancy and: 47, 56, 58, 60
salicylates: 42, 55
side effects: 15, 16, 28, 43, 52, 53, 57, 59, 61, 62, 103, 105, 108, 109, 111, 113, 115, 117, 119
treatment plans: 53

E

ecchymoses: 36, 58
edema (see fluid retention)
education of patients (see also Patient Information Sheets)
bleeding prevention: 36
fatigue management: 29, 30
flares: 46
fluid retention: 40
GI manifestations: 43
infection control: 30, 40, 48
joint function: 39
medications: 6, 39, 40, 44, 53
nutrition: 35, 49
pain management: 34
renal complications: 39, 40
skin protection: 33
weight control: 30
emotional
aspects of lupus: 5, 27-29, 41, 61
coping strategies: 68-70
physical repercussions: 67-69
rest: 5
side effects of drugs: 58
support for patients: 7, 30, 65-70
employment: 29
endocarditis: 21
endocrine: 58
environmental factors: 1, 13
epratuzumab: 16
ESR: 3, 22, 27, 35
etanercept: 14
etiology: 11-14, 16
exercise: 4, 28, 30, 33, 34, 37, 77, 79, 82, 84, 88, 95, 96
exophthalmos: 58

F

family issues: 34, 42, 65-69
fas gene: 13
fatigue: 3, 4, 7, 27-29, 35-37, 49, 55, 57, 67, 69, 76, 77, 79, 81, 83, 87, 97, 105, 108, 109, 111
fear: 7, 32, 42, 65-67, 75
Federal Working Group on Lupus: 18
fever: 2, 3, 6, 27-30, 43, 47, 48, 55, 57, 61, 81, 83, 84, 93, 105, 108, 109, 117
flare
allergies and: 49
defined: 1
exercise and: 4, 7
emotion and: 5
fever: 28, 30, 93


131


living with: 68, 69, 81, 89
medication: 6, 15, 16, 48, 54, 113
pregnancy and: 15, 45, 47, 99
symptomatic care: 7, 30
trigger: 13, 81, 115
fluid retention: 5, 28, 40, 54, 103
fluorescent lights: 90
Fluorescent treponemal antibody
absorption (FTA-ABS): 35
FTA-ABS: 35

G

G6PD deficiency: 56
gangrene: 32
gastrointestinal distress
bleeding: 21, 35, 36, 54
effects: 28
interventions: 6, 43, 55, 58
manifestations of lupus: 27, 42
side effects of drugs: 15, 54-56, 58, 60, 61, 95
gastric ulcers: 54
gene therapy: 13
genetics: 11-13, 18, 22, 66
glaucoma: 15, 44, 58, 85, 108
glucose 6-phosphate dehydrogenase
(G6PD) deficiency: 56
glucose, serum: 58
grief: 7, 29, 65, 66

H

hair loss (see alopecia)
halogen lights: 5, 82
hematologic
manifestations of lupus: 27, 35
side effects of drugs: 55, 56, 60
hemorrhagic cystitis: 15, 60
hepatitis: 21
herpes zoster: 48
hirsutism: 32, 58
HLA-DR2: 12
homemaker services: 8
hormones: 11, 13, 14, 16, 57, 62, 84
hormone replacement therapy: 17
human leukocyte antigen: 12
hydralazine: 2, 14
hydrocortisone: 57
hydroxychloroquine sulfate: 55, 113
hyperglycemia: 46, 58
hyperpigmentation: 31
hypertension: 5, 15, 28, 39, 46, 47, 54, 58, 99
hypopigmentation: 31

I

immunization: 6, 48, 82, 93, 113
immunosuppression: 58, 60
immunosuppressives: 6, 15, 29, 48, 59, 60, 61, 91, 109
indomethacin: 54
infection: 4, 6, 15, 16, 28-32, 35, 36, 40, 43, 46-48, 58-62, 81, 82, 89, 93, 97, 108, 109, 111, 113, 115, 117
inflammation: 2, 4, 12, 15, 22, 24, 36, 37, 44, 52, 54, 55, 57-59, 76, 79, 83, 85, 87, 103, 107, 109, 111, 117, 119
inflammatory diseases: 28, 115
infliximab: 14
injury: 41, 42, 44, 45, 82


insomnia: 28, 29, 62
intranuclear nucleic acid: 13
intrauterine devices: 46
intravenous immunoglobulins: 61, 119
isoniazid: 2, 14


J

Jaccoud's arthropathy: 34


joint pain: 33, 34, 52, 54, 55, 57, 61, 76, 79, 87


K

kaolin clotting time: 23
kidney
biopsy: 24, 38
damage: 38, 109
dialysis: 38
disease: 5, 12, 16, 23, 28, 40, 49, 58, 83, 96, 97
failure: 83
function: 97
glomerular filtration rate: 23
inflammation: 24, 117
side effects of drugs: 46, 59, 108, 115
transplantation: 16, 39
laboratory tests
amylase, serum: 43
ANA: 3, 4, 21
anti-La: 3, 22, 46
anti-Ro: 3, 22, 46
anti-Sm: 3, 4, 22
CBC: 3, 55, 56, 59, 60, 61
coagulation: 23
cortisol levels: 58
complement: 3, 12, 13, 22, 73, 74
C-reactive protein: 22
creatinine clearance: 23, 54
creatinine, serum: 23, 24, 39, 54, 61
ECG: 60, 61
electrolytes: 55, 58
enzyme: 22
ESR: 3, 22, 27, 35
FTA-ABS: 35
G6PD deficiency: 56
glucose, serum: 58
liver function: 56, 60, 61
MHA-TP: 35
platelets: 56, 60
renal function: 60, 61
stool: 55
urine: 23, 55
VDRL: 27, 35
WBC: 60
lesions: 30-33, 37, 38, 48, 54-56, 60, 61, 89
leukocytoclastic vasculitis: 37
leukopenia: 4, 21, 35, 36, 60, 62
Libman-Sacks lesions: 37
lifestyle changes: 30, 75
livedo reticularis: 32
liver: 3, 43, 46, 56, 58-62, 115
lupus anticoagulants: 23, 27
Lupus Foundation of America: 8, 69, 124
lymphopenia: 4, 27


M

malaria: 21, 55
malar rash (butterfly): 4
methotrexate: 43, 59-61, 90, 113
methyldopa: 14
methylprednisolone: 57
periungual erythema: 32
petechiae: 32, 36, 58, 89
phospholipid-binding plasma proteins: 22
photosensitivity: 3-5, 22, 27
physical rest: 4
platelets: 56, 60
pleurisy: 3, 27, 36, 37
pleuropericardial inflammation: 2
polymorphism: 13
prednisone: 15, 16, 21, 35, 57, 107
pregnancy and lactation: 55, 58, 60
complications of lupus: 47
flares: 15, 45, 47, 99
side effects of drugs: 47, 56, 58, 60
premature baby: 46, 99, 101
premature delivery: 6
procainamide: 2, 14
protein-phospholipid complexes: 22
protein/creatinine ratio: 23
pruritus: 39, 56
psychosis: 4, 27, 40, 41, 58
psychosocial factors (see also
emotional): 7, 28, 63, 64
coping skills: 68-70
diagnostic difficulties: 65
family issues: 66-68
pulmonary fibrosis: 60

R

range of motion: 87

rash: 1-5, 13, 31-33, 44-47, 55, 57, 61, 82, 85, 89, 90, 97, 100, 103, 105, 107, 113
Raynaud's phenomenon: 3, 32, 33, 43, 90, 91, 97
registry and repository: 18
remission: 1, 46, 64, 68, 82, 99, 100, 109
reproduction (see also contraception;
pregnancy and lactation): 6, 14, 15, 17, 45, 58, 60
research advances
etiology of lupus: 11-17
NIAMS role: 17, 18
treatment: 15-17, 70
respiratory: 36, 47
rest: 76, 77, 79, 81-83
emotional: 5
physical: 4
retinal damage: 44, 56, 105
rheumatoid arthritis: 2, 14, 16, 21, 33, 55, 59, 87, 115
ribonucleoprotein complexes: 11, 13
rituximab: 16

S

Safety of Estrogen in Lupus
Erythematosus National Assessment: 17
salicylates: 42, 55
Salmonella: 48
seizures: 3, 4, 27, 40, 41, 47, 83, 84
serositis: 4
Sjogren's syndrome: 21, 22, 43, 44
skin
biopsy: 31
condition/disease (see also lesion,
rash): 12, 89-91
infection: 28, 48
ulcers: 32, 89
SLE Foundation: 8, 69, 124
smoking: 33, 38, 90
Specialized Centers of Research: 18
spouse/partner of patient: 66, 100
stillbirth: 28, 46, 99
stress: 2, 5, 13, 28, 33, 75, 77, 79, 81, 82, 90, 91
stroke: 27, 40, 84, 96
subacute cutaneous lupus: 31, 32
sunlight: 4, 5, 13, 31, 67, 81, 103
sunscreen: 5, 33, 90
support systems: 7, 8, 31
surgery: 6, 57, 81, 82, 107
systemic sclerosis: 21
symptoms of SLE (see also under specific symptoms): 3, 27-29
cardiopulmonary: 36-38
CNS: 40-42
dermatological: 31-33
gastrointestinal: 42, 43
hematologic: 35, 36
infection: 47, 48
musculoskeletal: 33, 34
nutrition-related: 49, 50
ophthalmologic: 44, 45
psychological: 29
renal: 38-40

T

tendinitis: 34, 87
tendon rupture: 34, 87
tinnitus: 44, 55, 56
treatment of SLE (see also drugs; and under specific regimens): 3-8, 15-17
biologic agents: 15
hormones: 15
thalidomide: 62
thrombocytopenia: 4, 21, 27, 35, 36, 46, 60
thrombosis: 22, 23, 35, 37, 38, 62
tuberculosis: 21, 58

U

ulcers: 32, 89
urinary: 28-30, 39, 40, 48, 54, 58, 60, 117
urticaria: 58

V

vaginal ulcers: 89
valvular heart disease: 27, 37
vasculitis: 27, 37, 40, 42, 43, 61, 89, 119
VDRL: 27, 35
venous thrombosis: 37
vertigo: 41
viruses: 13, 14
visual impairment: 44
VNA: 8
vocational rehabilitation: 8

W

WBC: 21, 24, 27-30, 35, 58, 60
weight changes: 28, 49
weight gain: 5, 15, 28, 29, 39, 58, 67, 76, 95, 100, 108
weight loss: 5, 28, 49, 84, 95, 108
wound healing: 32, 58, 108